LSM-775

LSM-775
Clinical data
Other namesLSM775; LSM; SLM; N-Morpholinyllysergamide; Lysergic acid morpholide; LA-Morph; LA-Morpholide; Morpholine lysergamide; 6-Methyl-8β-(morpholin-4-ylcarbonyl)-9,10-didehydroergoline
Routes of
administration		Oral
Drug classSerotonin receptor modulator; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
Legal status
Legal status
Identifiers
  • [(6aR,9R)-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinolin-9-yl]-morpholin-4-ylmethanone
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H23N3O2
Molar mass337.423 g·mol−1
3D model (JSmol)
  • O=C(N1CCOCC1)[C@@H]5C=C4c2cccc3c2c(c[nH]3)C[C@H]4N(C)C5
  • InChI=1S/C20H23N3O2/c1-22-12-14(20(24)23-5-7-25-8-6-23)9-16-15-3-2-4-17-19(15)13(11-21-17)10-18(16)22/h2-4,9,11,14,18,21H,5-8,10,12H2,1H3/t14-,18-/m1/s1 checkY
  • Key:OTQWCDNEJVKXKG-RDTXWAMCSA-N checkY
  (verify)

LSM-775, also known as N-morpholinyllysergamide or as lysergic acid morpholide, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD).

Use and effects

LSM-775 is less potent than LSD but is reported to have some LSD-like effects at doses ranging from 75 to 1,000 μg orally and a shorter duration. It may only produce weak or threshold psychedelic effects in humans. There have been said to be fewer signs of cardiovascular stimulation and peripheral toxicity with LSM-775 compared to LSD. On the other hand, more recent reports suggest that LSM-75 produces considerable nausea and feelings of lethargy and sedation.

Interactions

Pharmacology

Pharmacodynamics

LSM-775 is a potent full agonist of the serotonin 5-HT1A receptor and a potent partial agonist of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors. It does not produce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. However, LSM-775 can robustly increase head twitches if it is coadministered with the serotonin 5-HT1A receptor antagonist WAY-100635. These findings indicate that serotonin 5-HT1A receptor activation suppresses the psychedelic-like effects of LSM-775.

Chemistry

Synthesis

The chemical synthesis of LSM-775 has been described.

Analogues

Analogues of LSM-775 include the cyclized lysergic acid piperidide (LA-Pip), lysergic acid azepane (LA-Azepane), lysergic acid pyrrolidide (LA-Pyr; LPD-824), lysergic acid pyrrolinide (LPN), and lysergic acid 2,4-dimethylazetidide (LA-Az, LSZ) and the non-cyclized LEO, LA-MeO, ergometrine, and methylergometrine, among others.

History

LSM-775 was first described in the scientific literature by Albert Hofmann and colleagues by 1955. It emerged as a novel designer drug in 2013.

Society and culture

Canada

LSM-775 is not a controlled substance in Canada as of 2025.

United States

LSM-775 is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.

See also